Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
What's the purpose of the trial?
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
The names of the study drugs involved in this study are:
* Iberdomide (a type of cereblon E3 ligase modulator)
* Elotuzumab (a type of monoclonal antibody)
* Dexamethasone (a type of steroid)
Trial status
Not yet accepting
Phase
Phase 1/2
Enrollment
49
Last Updated
2 weeks ago
Participating Centers
There are 3 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Dexamethasone
- Elotuzumab
- Iberdomide
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Not yet accepting
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.